Canada: Federal Court Of Appeal Considers Data Protection Provisions…Again

The recent decision of the Federal Court of Appeal (FCA) in Minister of Health v. Celgene Inc. (Celgene) marks the second split decision of that court in as many months on the data protection provision of the Food and Drug Regulations (the FDR).

Our previous bulletin, Closer Than They Appear: Federal Court of Appeal Considers Definition of "Innovative Drug", reported on the decision of the FCA in Takeda Canada Inc. v. The Minister of Health (Takeda), denying data protection for Takeda's DEXILANT drug on the ground that it did not qualify as an "innovative drug". Although the FCA in Celgene considered a different aspect of the definition of "innovative drug", data protection was also denied on the ground that the product at issue in that case did not fall within the definition.

BACKGROUND

The question in the Celgene appeal was whether Celgene's THALOMID drug falls within the definition of an "innovative drug" in the FDR. Under the FDR, an innovative drug, once approved by the Minister of Heath (the Minister) by way of a Notice of Compliance (NOC), is listed on the Register of Innovative Drugs (the Register).

Under the FDR, an approved drug that is listed on the Register benefits from a period of market exclusivity for eight years starting from the date of approval. During that period, a generic manufacturer may not obtain an NOC to market a drug based on the data filed with Health Canada for approval of the innovative drug.

In the FDR, an "innovative drug" is defined as "a drug that contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph" [emphasis added].

TRIAL DECISION

In the Federal Court of Canada (FCC), Celgene challenged the Minister's decision not to list THALOMID on the Register. The FCC considered whether the prior approval of thalidomide in the early 1960s constituted an approval within the definition of "innovative drug" in the FDR. Shortly after its first approval in November 1960, thalidomide was withdrawn from the Canadian market in April 1962 due to the determination that the drug caused serious side effects, most significantly severe birth defects.

The FCC held that THALOMID was an "innovative drug" and should be listed on the Register and benefit from the eight years of data protection. The FCC looked at the purpose and intent of the FDR to encourage innovation and the development of new drugs, and found that Celgene had taken a compound that had been banned and had produced entirely new data showing that the drug could be useful and potentially lifesaving under the right circumstances.

The FCC further held that to deny data protection in this case would be inconsistent with Canada's international treaty obligations under the North American Free Trade Agreement and the Agreement on Trade-Related Aspects of Intellectual Property Rights. For further discussion of the FCC decision, please see our October 2012 Blakes Bulletin on Life Sciences: I Want a New Drug: Developments in Data Protection for Innovative Drugs.

APPEAL DECISION

In a split decision, the FCA reversed the FCC and held that THALOMID does not qualify as an "innovative drug." Celgene argued that the word "approved" refers to the status of the drug at the time the request for approval of the drug is submitted by the innovator, effectively interpreting the term "previously approved" as "currently approved". Writing for the majority, Justice Gauthier held that the words did not lend themselves to this interpretation and further disagreed with Celgene's argument that such an interpretation was consistent with the intention of the FDR and the relevant treaty provisions. Justice Gauthier applied a literal interpretation of the term "previously approved".

Justice Gauthier stated that the legislators clearly intended to avoid any duplication of the market exclusivity period and that, while there may be no such duplication in this case, this would not necessarily be true if Celgene's interpretation of the term "previously approved" to mean "currently approved" were applied in all cases. She also noted that Celgene's interpretation could apply to any drug which had been withdrawn because of a Minister's decision or even to a drug that was voluntarily withdrawn. While Justice Gauthier acknowledged the exceptional history of thalidomide, she found that this history did not provide sufficient basis to create an exception in the interpretation of the FDR.

Justice Nadon dissented from the majority and would have dismissed the appeal and upheld the decision of the FCC to grant data protection. Like the majority, Justice Nadon focused on the interpretation of the term "previously approved". However, he held that the circumstances surrounding the revocation of thalidomide's approval and removal from the Canadian market in 1962 amounted to a "nullification" of the previous approval so that thalidomide was not "previously approved" and was eligible for data protection.

Although Justice Nadon would have upheld the decision of the FCC, he explicitly distanced his view from the reasoning of the FCC. Specifically, while he found that the FCC's focus on the purpose and intent of the data protection regime was "helpful, and concurrent in result", it was not determinative of his holdings on appeal since his position could be supported merely by a proper interpretation of "previously approved".

Nonetheless, Justice Nadon's reasons do consider the purpose and intention of the data protection regime. In particular, he highlighted that, given thalidomide's revoked approval, there was no product available to serve as a reference product for THALOMID. As such, Celgene was required to prepare and submit the voluminous data required to support a New Drug Submission rather than the Abbreviated New Drug Submission that a generic manufacturer would be able to submit. Justice Nadon found that this bolstered the rationale for extending data protection to THALOMID.

Justice Nadon's strong dissent in this case follows the dissent of Justice Stratas in the Takeda case. Although the cases focused on different aspects of the definition of "innovative drug", in both cases the majority decision held that the literal meaning of the definition was clear. Although both majority decisions considered the purpose of the legislation, including compliance with Canada's international treaty obligations, the decisions turned on the view that the wording of the statutory provision was, on its face, unambiguous.

The dissenting justices in each case, while not expressly adopting a different approach to the interpretation of the statute, appeared to give greater weight to the underlying purpose and context of the statutory provisions and would have adopted an approach that would have more specifically taken into account the amount of time, effort and resources expended by the drug manufacturers when deciding whether to extend data protection.

The majority decisions in these cases, which emphasize the literal interpretation of the statutory provisions, clearly set the precedent for future cases dealing with the data protection regime in the FDR. However, the strong dissents in these cases do illustrate that some uncertainty may still exist when interpreting these provisions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
26 Oct 2018, Other, Vancouver, Canada

Cybersecurity, including data privacy and security obligations, has become a critical chapter in every company’s risk management playbook.

30 Oct 2018, Other, Toronto, Canada

Please join us for discussions on recent updates and legal developments in pension and employee benefits as well as employment law issues.

12 Nov 2018, Other, Toronto, Canada

Stories aren’t falsehoods. Stories are the root of all effective human communications: they motivate, animate and clarify. If you aren’t telling stories, you probably aren’t getting your point across.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions